ArticleInfection and immunity1999
Assessment of immunity to mycobacterial infection with luciferase reporter constructs.
Article in Infection and immunity, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed.
- Influenza coinfection inhibits control of mycobacterial infection in a human challenge model.Nature communications · 2026Article
- Real-time bioluminescence imaging of mycobacteria with Akaluc: a novel method for monitoring drug efficacy.Scientific reports · 2026Article
- Optimizing the Antibiotic Potency and Metabolic Stability of Pyridomycin Using a Semisynthetic Approach.Journal of medicinal chemistry · 2026Article
- Assessment of Innovative Dry Powders for Inhalation of a Synergistic Combination AgainstPharmaceutics · 2025Article
- Antimycobacterial activity of the plectasin derivative NZ2114.Frontiers in microbiology · 2025Article
- A modified mycobacterial growth inhibition assay for the functional assessment of vaccine-mediated immunity.NPJ vaccines · 2024Article
- A high-throughput target-based screening approach for the identification and assessment ofMicrobiology spectrum · 2024Article
- Activity of Bacteriophage D29 Loaded on Nanoliposomes against Macrophages Infected withDiseases (Basel, Switzerland) · 2023Article
- Telacebec Interferes with Virulence Lipid Biosynthesis Protein Expression and Sensitizes to Other Antibiotics.Microorganisms · 2023Article
- Mechanisms of aPharmaceutics · 2023Article
- Immunogenicity of PE18, PE31, and PPE26 proteins fromFrontiers in immunology · 2023Article
- Structure and ion-release mechanism of PeLife · 2021Article
- In-vivo expressed Mycobacterium tuberculosis antigens recognised in three mouse strains after infection and BCG vaccination.NPJ vaccines · 2021Article
- A broad spectrum anti-bacterial peptide with an adjunct potential for tuberculosis chemotherapy.Scientific reports · 2021Article
- Innate Immune Responses ofFrontiers in cellular and infection microbiology · 2021Article
- Addressing Latent Tuberculosis: New Advances in Mimicking the Disease, Discovering Key Targets, and Designing Hit Compounds.International journal of molecular sciences · 2020Review
- Article
- Article
- Effective delivery of the anti-mycobacterial peptide NZX in mesoporous silica nanoparticles.PloS one · 2019Article
- A novel derivative of the fungal antimicrobial peptide plectasin is active against Mycobacterium tuberculosis.Tuberculosis (Edinburgh, Scotland) · 2018Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Protective immunity to mycobacterial infection is incompletely understood but probably involves the coordinated interaction of multiple cell types and cytokines. With the aim of developing assays that might provide a surrogate measure of protective immunity, we have investigated the use of recombinant mycobacteria carrying luciferase reporter enzymes to assess the effectiveness of antimycobacterial immunity in model systems. Measurement of luminescence was shown to provide a rapid and simple alternative to the counting of CFU as a means of monitoring mycobacterial viability. We describe optimization of a luciferase reporter strain of Mycobacterium tuberculosis and demonstrate its application for the study of mycobacterial interactions with host cells in tissue culture and the rapid assessment of vaccine efficacy in a murine model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.